Ligand validation:3KF3

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3KF3 designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3KF3_NAG_A_3001	47%	56%	0.128	0.865	0.57	1.11	-	1	0	0	100%	0.9333
3KF3_NAG_B_3001	44%	46%	0.139	0.865	0.59	1.5	-	1	0	0	100%	0.9333
3KF3_NAG_B_4001	31%	62%	0.153	0.821	0.56	0.88	-	-	1	0	100%	0.9333
3KF3_NAG_A_4001	29%	55%	0.163	0.822	0.55	1.17	-	2	0	0	100%	0.9333
3KF3_NAG_A_5001	12%	57%	0.226	0.749	0.57	1.07	-	1	0	0	100%	0.9333
3KF3_NAG_A_1001	5%	52%	0.295	0.699	0.57	1.28	-	2	0	0	100%	0.9333
3KF3_NAG_B_5001	5%	52%	0.296	0.69	0.47	1.39	-	1	0	0	100%	0.9333
6S2B_NAG_B_601	86%	51%	0.083	0.952	0.55	1.32	-	3	0	0	100%	0.9333
6S1T_NAG_B_602	78%	65%	0.098	0.94	0.48	0.83	-	1	0	0	100%	0.9333
3U75_NAG_C_1394	55%	34%	0.133	0.901	0.59	2.08	-	5	0	0	100%	0.9333
3U14_NAG_B_1219	53%	10%	0.151	0.914	1.74	2.78	2	6	0	0	100%	0.9333
3KF5_NAG_A_4001	44%	44%	0.185	0.913	0.45	1.71	-	4	1	0	100%	0.9333
1OC7_NAG_A_500	100%	60%	0.04	0.991	0.61	0.9	-	1	0	0	100%	0.9333
1OC6_NAG_A_500	100%	67%	0.041	0.988	0.46	0.8	-	1	0	0	100%	0.9333
1UWC_NAG_A_262	100%	54%	0.046	0.99	0.81	0.95	-	-	0	0	100%	0.9333
6ZE6_NAG_B_703	99%	52%	0.044	0.984	0.78	1.07	-	2	0	0	100%	0.8667
6ZE2_NAG_B_704	99%	56%	0.042	0.979	0.73	0.95	-	1	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.